FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020170651> ?p ?o ?g. }

• W2020170651 endingPage "328" @default.
• W2020170651 startingPage "323" @default.
• W2020170651 abstract "Abstract Sodium 3,4-diaminonaphthalene-1-sulfonate (CRA) is a compound, synthesised by our group from Congo Red (CR), that is active in preventing the pathological conversion of normal prion protein (PrP). As the precise mechanisms controlling the ways in which prions are distributed and infect the brain and other organs are not fully understood, studying the pharmacokinetics of drugs that are active against prions may clarify their targets and their means of inhibiting prion infection. This paper describes the pharmacokinetics of CRA in plasma, spleen and brain after single or repeated intraperitoneal or subcutaneous administration, as determined by means of specific and sensitive fluorimetric HPLC. A single intraperitoneal administration led to peak plasma CRA concentrations after 15 min, followed by biphasic decay with an apparent half-life of 4.3 h. After subcutaneous administration, Tmax was reached after 30 min, and was followed by a similar process of decay: Cmax and the AUC0-last were 25% those recorded after intraperitoneal administration. The mean peak concentrations and AUCs of CRA after a single intraperitoneal or subcutaneous administration in peripheral tissue (spleen) were similar to those observed in blood, whereas brain concentrations were about 2% those in plasma. After repeated intraperitoneal or subcutaneous doses, the Cmax values in plasma, brain and spleen were similar to those observed at the same times after a single dose. After repeated intraperitoneal doses, CRA was also found in the ventricular cerebrospinal fluid at concentrations of 1.8 + 0.2 μg mL−1, which is similar to, or slightly higher than, those found in brain. Brain concentrations may be sufficient to explain the activity of CRA on PrP reproduction in the CNS. However, peripheral involvement cannot be excluded because the effects of CRA are more pronounced after intraperitoneal than after intracerebral infection." @default.
• W2020170651 created "2016-06-24" @default.
• W2020170651 creator A5000835900 @default.
• W2020170651 creator A5006732921 @default.
• W2020170651 creator A5007984291 @default.
• W2020170651 creator A5013556761 @default.
• W2020170651 creator A5027019614 @default.
• W2020170651 creator A5028284203 @default.
• W2020170651 creator A5043830478 @default.
• W2020170651 creator A5082213813 @default.
• W2020170651 date "2004-03-01" @default.
• W2020170651 modified "2023-09-27" @default.
• W2020170651 title "Pharmacokinetics and distribution of sodium 3,4-diaminonaphthalene-1-sulfonate, a Congo Red derivative active in inhibiting PrPres replication" @default.
• W2020170651 cites W1521032053 @default.
• W2020170651 cites W1523600076 @default.
• W2020170651 cites W1566848521 @default.
• W2020170651 cites W1610246685 @default.
• W2020170651 cites W1829344915 @default.
• W2020170651 cites W1946570873 @default.
• W2020170651 cites W1979533060 @default.
• W2020170651 cites W1984344104 @default.
• W2020170651 cites W2011927539 @default.
• W2020170651 cites W2014252309 @default.
• W2020170651 cites W2016117056 @default.
• W2020170651 cites W2030927274 @default.
• W2020170651 cites W2032843390 @default.
• W2020170651 cites W2033766120 @default.
• W2020170651 cites W2045413414 @default.
• W2020170651 cites W2054705140 @default.
• W2020170651 cites W2066662038 @default.
• W2020170651 cites W2068202287 @default.
• W2020170651 cites W2079521468 @default.
• W2020170651 cites W2082573664 @default.
• W2020170651 cites W2083983846 @default.
• W2020170651 cites W2116988453 @default.
• W2020170651 cites W2134658084 @default.
• W2020170651 cites W2154143507 @default.
• W2020170651 cites W2163981524 @default.
• W2020170651 cites W2169109742 @default.
• W2020170651 cites W2324660492 @default.
• W2020170651 cites W4252772420 @default.
• W2020170651 doi "https://doi.org/10.1211/0022357022854" @default.
• W2020170651 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15025857" @default.
• W2020170651 hasPublicationYear "2004" @default.
• W2020170651 type Work @default.
• W2020170651 sameAs 2020170651 @default.
• W2020170651 citedByCount "1" @default.
• W2020170651 crossrefType "journal-article" @default.
• W2020170651 hasAuthorship W2020170651A5000835900 @default.
• W2020170651 hasAuthorship W2020170651A5006732921 @default.
• W2020170651 hasAuthorship W2020170651A5007984291 @default.
• W2020170651 hasAuthorship W2020170651A5013556761 @default.
• W2020170651 hasAuthorship W2020170651A5027019614 @default.
• W2020170651 hasAuthorship W2020170651A5028284203 @default.
• W2020170651 hasAuthorship W2020170651A5043830478 @default.
• W2020170651 hasAuthorship W2020170651A5082213813 @default.
• W2020170651 hasBestOaLocation W20201706511 @default.
• W2020170651 hasConcept C110121322 @default.
• W2020170651 hasConcept C112705442 @default.
• W2020170651 hasConcept C126322002 @default.
• W2020170651 hasConcept C134306372 @default.
• W2020170651 hasConcept C178790620 @default.
• W2020170651 hasConcept C185592680 @default.
• W2020170651 hasConcept C203014093 @default.
• W2020170651 hasConcept C22979827 @default.
• W2020170651 hasConcept C2776390293 @default.
• W2020170651 hasConcept C2779651940 @default.
• W2020170651 hasConcept C2780159080 @default.
• W2020170651 hasConcept C2780931953 @default.
• W2020170651 hasConcept C33923547 @default.
• W2020170651 hasConcept C537181965 @default.
• W2020170651 hasConcept C71924100 @default.
• W2020170651 hasConcept C98274493 @default.
• W2020170651 hasConceptScore W2020170651C110121322 @default.
• W2020170651 hasConceptScore W2020170651C112705442 @default.
• W2020170651 hasConceptScore W2020170651C126322002 @default.
• W2020170651 hasConceptScore W2020170651C134306372 @default.
• W2020170651 hasConceptScore W2020170651C178790620 @default.
• W2020170651 hasConceptScore W2020170651C185592680 @default.
• W2020170651 hasConceptScore W2020170651C203014093 @default.
• W2020170651 hasConceptScore W2020170651C22979827 @default.
• W2020170651 hasConceptScore W2020170651C2776390293 @default.
• W2020170651 hasConceptScore W2020170651C2779651940 @default.
• W2020170651 hasConceptScore W2020170651C2780159080 @default.
• W2020170651 hasConceptScore W2020170651C2780931953 @default.
• W2020170651 hasConceptScore W2020170651C33923547 @default.
• W2020170651 hasConceptScore W2020170651C537181965 @default.
• W2020170651 hasConceptScore W2020170651C71924100 @default.
• W2020170651 hasConceptScore W2020170651C98274493 @default.
• W2020170651 hasIssue "3" @default.
• W2020170651 hasLocation W20201706511 @default.
• W2020170651 hasLocation W20201706512 @default.
• W2020170651 hasOpenAccess W2020170651 @default.
• W2020170651 hasPrimaryLocation W20201706511 @default.
• W2020170651 hasRelatedWork W2020170651 @default.
• W2020170651 hasRelatedWork W2370929226 @default.
• W2020170651 hasRelatedWork W2379280247 @default.
• W2020170651 hasRelatedWork W2766550598 @default.

• next